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-Lactams are arguably one of the most important
heterocyclic skeletons in organic chemistry. Because of their
unique biological properties, -lactam derivatives have been
the object of intense investigation in synthetic and medicinal
chemistry areas. Since the discovery of penicillin, a number
of bicicylic -lactams have found broad applicability in
antibacterial therapy. Aside from penicillin analogues, many
cephalosporins, carbapenems, oxapenams, etc., are also
currently used as effective weapons in the fight against
bacteria.1,2 More recently, the significance of -lactams has
reached new frontiers, mostly because of the discovery of
derivatives that show biological activities such as inhibition
of prostate specific antigen,3 thrombin,4 human cytomega-
lovirus protein,5 human leukocyte elastase,6 cholesterol
absorption,7 cysteine protease,8 and human fatty acid amide
hydrolase;9 as well as neuroprotective action.10
For more than a decade, the rapid emergence of bacterial
resistance has caused a serious concern in the antiinfectious
therapy, mostly due to bacterial mutation and gene ex-
change.11 Consequently, a number of novel strategies directed
to the synthesis of new -lactam antibiotics have been
reported.12 Among them, preparation of multicyclic -lactam
compounds have emerged as an interesting alternative,
leading to a new generation of antibiotics known as trinems
(1), with good stability against -lactamase and dehydro-
peptidase deactivation,13 and also to compounds with potent
activity against class A and class C -lactamases (2) (Figure
1).14 Moreover, some multicyclic -lactams (3) have found
interest in the area of cholesterol absorption inhibition,15
while other related structures (4) have shown significant
activity against different human cancer cell lines.16
In recent years, we have developed a series of solid-
supported synthetic strategies for the generation of libraries
of -lactam compounds.17 We envisioned that the Staudinger
reaction between imines and immobilized ketenes18 would
be useful for achieving an efficient solid-phase synthesis of
biologically promising multicyclic -lactams.
To establish a solid-phase route to multicyclic carba-
cepham derivatives, the immobilized 4-hydroxyphenoxyace-
tic acid (5) was used as precursor for the in situ formation
of the ketene 6 (Scheme 1). Resin-bound acid 5 was obtained
in two steps from Wang resin.18 Thus, ketene 6 reacts with
phenantridine (7) to yield the corresponding C-3-anchored
tetracyclic -lactam 9, which was corroborated by gel-phase
13C NMR19 where the spectrum showed the presence of the
-lactam fused to the 6-membered ring, especially from the
peaks at 57 and 89 ppm, corresponding to C-6 and C-7,
respectively. Final treatment of the resin 9 with 10%
trifluoroacetic acid in CH2Cl2 afforded the carbacepham
analogue 10 in a 57% overall yield, after isolation by column
chromatography (based on the initial loading level of the
Wang resin). It is interesting to note that, under homogeneous
phase reaction conditions, similar products were obtained
in low yield and as a mixture of isomers.15
1H NMR coupling constant between hydrogens at C-6
and C-7 positions of the -lactam ring denotes a 6,7-trans
stereochemistry. This is clearly in agreement with a
ketene-imine mechanism for the -lactam formation
(Scheme 2). Being 7 a cyclic imine, the orthogonal ap-
proach between the reactant species lead to the zwitterionic
intermediate 11 which, by conrotatory electrocyclization,
generates the 6,7-trans product (9).20
This solid-phase strategy was used for the generation of a
small array of 1,2-benzofused carbacepham employing a
series of 3,4-dihydroisoquinoline derivatives as imine com-
ponent (Scheme 3).21 Interestingly, when 3,4-dihydroiso-
quinoline (12a, R ) R′ ) H) was used as the cyclic imine,
formation of the expected benzofused carbacepham 13a was
clear by gel-phase 13C NMR, however, separation from the
solid support has proved to be unsuccessful, probably due
to the lack of stability of the tricyclic -lactam under the
cleavage conditions.
Better results were obtained with other 3,4-dihydroiso-
quinolines. Thus, 6,7-dimethoxy-1-aryl-3,4-dihydroisoqu-
inolines (12b-e) were synthesized by a Bishler-Napieralski
reaction, using phosphorus oxychloride as dehydrating
agent.22 To perform the solid-phase version of the
Staudinger cyclization, the immobilized carboxylic acid
5 was treated successively with the 6,7-dimethoxy-1-aryl-
3,4-dihydroisoquinoline (12b-e) (5 equiv), triethylamine
(6 equiv), and Mukaiyama’s reagent (8) (3 equiv),
followed by refluxing in chloroform for 2 h, and the
reaction was repeated to ensure complete formation of
the product (13b-e) (Scheme 3).23 Characterization of
the resin-bound benzofused carbacephams 13b-e were
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achieved by solid-phase FTIR24 spectra that showed the
-lactam carbonyl absorption peak at ∼1772 cm-1, and
the gel-phase 13C NMR (Figure 2). The cleavage of the
immobilized tricyclic -lactams from the resin was carried
out with 10% trifluoroacetic acid in CH2Cl2 for 1 h at
room temperature. The corresponding benzofused carba-
cephams 14b-e were obtained in very good overall yield,
after isolation by column chromatography.
A nuclear Overhauser effect (NOE) experiment allowed
us to corroborate the relative configuration of the substit-
uents at C-6 and C-7 positions. 1H NMR NOE experiments
demonstrated that these substituents are in a cis relation-
ship. As seen in Figure 3, the experiment was carried out
on carbacepham 14d, and shows that irradiation at the
singlet at 5.36 ppm, corresponding to H-7, causes a clear
enhancement of the signal at 6.74 ppm, assigned to the
H-9 of the fused aromatic ring. The presence of the aryl
group bound to C-6 places both substituents at C-6 and
C-7 positions at the same face of the bicyclic azetidinone-
piperidine system.
In conclusion, it is well-known the biological importance
of bicyclic -lactams, which include penicillins, cefa-
losporins, penems, carbapenems, carbacephems, oxaceph-
ems, and clavams, among other structures. Despite their
undoubted significance, very few solid-phase methods
have been reported in literature for the construction of
multicyclic -lactam systems;25 actually, most of the
procedures are related to the preparation of monocyclic
-lactams (monobactams).26 Now, we are extending the
scope of these methodologies by adding an efficient
synthetic sequence for the solid-phase preparation of
multicyclic -lactam derivatives. Key step is the cycload-
dition reaction between an immobilized ketene and
different cyclic imines to afford the corresponding ben-
zofused carbacepham derivatives in high yield for the
overall synthetic sequence. Stereoselectivity at the ste-
reogenic centers of the newly formed -lactam ring is in
agreement with a ketene-imine mechanism. We believe
that the in situ generated immobilized ketenes18 have
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Staudinger reaction to the development of biologically
promising compounds.
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